VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Anheuser-Busch InBev SA/NV vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Anheuser-Busch InBev SA/NV
ABI · Euronext Brussels
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Anheuser-Busch InBev SA/NV's moat claims, evidence, and risks.
View ABI analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Anheuser-Busch InBev SA/NV leads (75 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Anheuser-Busch InBev SA/NV has 6 segments (28.6% in Middle Americas); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Primary market structure: Duopoly vs Oligopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: Anheuser-Busch InBev SA/NV has 5 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Anheuser-Busch InBev SA/NV
Middle Americas
Beer and malt-based beverages (plus growing no-alcohol and Beyond Beer)
Mexico, Central America, and Caribbean (AB InBev reporting segment)
Retailers and on-premise outlets
Brewer / brand owner + route-to-market operator
28.6%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Anheuser-Busch InBev SA/NV strengths
Gilead Sciences, Inc. strengths
Segment mix
Anheuser-Busch InBev SA/NV segments
Full profile >North America
Oligopoly
Middle Americas
Duopoly
South America
Oligopoly
EMEA
Oligopoly
Asia Pacific
Competitive
Global Export & Holding Companies
Competitive
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.